50 stories mentioning BIIBUpdated 4h ago
Every FINWIRES story that references BIIB, newest first.
Biogen (BIIB) shares rose 2.3% in Wednesday afternoon trading after UBS upgraded the biotechnology company's stock to buy from neutral and boosted its price target to $225 per share from $185.Trading volume exceeded 700,000 shares, compared with a daily average of over 1.2 million.Price: $190.25, Change: $+4.30, Percent Change: +2.31%
Biogen's (BIIB) Q1 earnings call will likely focus on data from the BIIB080 Alzheimer's disease study expected mid-year, Oppenheimer analysts said in a note emailed Wednesday.The company is scheduled to report its Q1 financial results on April 29.Oppenheimer analysts expect the company to post Q1 adjusted earnings of $2.96 a share. Analysts polled by FactSet expect $2.99.Oppenheimer said that BIIB080's phase 2 results are Biogen's largest near-term catalyst, as competitors' topline misses underscore high barriers to entry in the anti-tau field.Analysts said that another key focus in the earnings call will be the implications of Biogen's deal to acquire Apellis Pharmaceuticals (APLS).Oppenheimer has an outperform rating on the stock and a $275 price target.Price: $190.50, Change: $+4.55, Percent Change: +2.44%
Biogen (BIIB) has an average rating of overweight and mean price target of $213.07, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $191.67, Change: $+5.72, Percent Change: +3.07%
Biogen (BIIB) has an average rating of overweight and mean price target of $213.07, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Health care stocks were leaning lower premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) declining by 0.4% and the iShares Biotechnology ETF (IBB) down 0.5%.Biogen (BIIB) has agreed to acquire TJ Biopharma's rights to the felzartamab antibody in the Greater China Region under a definitive agreement, the companies said. Biogen shares were up more than 1% pre-bell.AstraZeneca (AZN) said its pivotal phase 3 study of tozorakimab demonstrated a "significant" reduction in the annual rate of moderate-to-severe chronic obstructive pulmonary disease, or COPD, exacerbations in trial participants. Shares of AstraZeneca were down more than 1% premarket.ANI Pharmaceuticals (ANIP) stock was up more than 1% after the company said it has received US Food and Drug Administration approval and launched Pimozide Tablets in 1 mg and 2 mg doses, the generic version of Orap, with 180-day Competitive Generic Therapy exclusivity.
Health care stocks were flat to lower premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) inactive and the iShares Biotechnology ETF (IBB) down 0.5%.Biogen (BIIB) has agreed to acquire TJ Biopharma's rights to the felzartamab antibody in the Greater China Region under a definitive agreement, the companies said. Biogen shares were up more than 1% pre-bell.
Biogen (BIIB) has an average rating of overweight and mean price target of $210.96, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index up 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.6%.The iShares Biotechnology ETF (IBB) climbed 2.1%.In corporate news, Johnson & Johnson (JNJ) lifted its full-year outlook on Tuesday as the healthcare products conglomerate's Q1 results surpassed Wall Street's expectations. Its shares rose 1.1%.Eli Lilly (LLY) has agreed to buy CrossBridge Bio for up to $300 million in cash, the pre-clinical biotechnology firm said Tuesday. Lilly shares were down 0.6%.Novo Nordisk (NVO) has received the Medicines and Healthcare products Regulatory Agency approval for a new single-dose 7.2 mg of Wegovy to treat adults with obesity, the UK regulator said. Novo shares climbed 3.5%.Biogen (BIIB) shares rose 1.5% after Piper Sandler upgraded the stock to overweight from neutral and boosted its price target to $214 from $177.Avanos Medical (AVNS) shares surged 69% after the company said Tuesday it agreed to be acquired by American Industrial Partners affiliates in an all-cash deal valuing the company at roughly $1.27 billion.
Biogen (BIIB) shares were up about 1.5% in Tuesday trading after Piper Sandler upgraded the stock to overweight from neutral and boosted its price target to $214 from $177.Trading volume stood at more than 934,000 shares, compared with a daily average of nearly 1.3 million.Price: $179.10, Change: $+2.73, Percent Change: +1.55%
Biogen (BIIB) has an average rating of overweight and mean price target of $210.96, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Showing 41-50 of 50
